TransMedics Group, Inc. — Third Quarter 2026 Earnings Summary

TransMedics Group reported third-quarter 2026 total revenue of $203.0 million, representing a 41% increase year-over-year driven by higher organ transplant volumes and the inclusion of PAD Aviation logistics services. The company achieved net income of $17.1 million, or $0.46 per diluted share, while raising its full-year 2026 revenue guidance to a range of $764 million to $774 million. Recent operational milestones include FDA approvals for the ENHANCE Heart Part B and DENOVO Lung trials, the commencement of European transplant operations in Italy, and the appointment of a new Chief Financial Officer.